All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
7 results for "Cancer" and "Head and Neck Cancers" and "Esophagus"
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients, NCCAPS Study. How does COVID19 affect the outcomes of people undergoing cancer treatment? How does having cancer affect COVID-19?
Protocol No
NCI-COVID-NCCAPS
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
MRTX849 is an investigational drug that is designed to target proteins produced by a specific
gene mutation (KRAS G12C mutation) that is thought to cause cancer cells to grow. MRTX849
is designed to block this mutant protein and thereby prevent the growth and spread of the cancer.
gene mutation (KRAS G12C mutation) that is thought to cause cancer cells to grow. MRTX849
is designed to block this mutant protein and thereby prevent the growth and spread of the cancer.
Protocol No
MIRATI-849-002
Sub Category
A Phase I Study of GNX102 in Patients with Advanced Solid Tumors
This new medicine, GNX102, is an antibody that binds to a certain target on the surface of the cancer cells and may kill the cancer cells.
The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.
The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.
Protocol No
GLYCONEX-GNX-001
Sub Category
A Phase 1/1b, First-In-Human, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Oral TP-1454 Alone And In Combination With Ipilimumab And Nivolumab
The primary purpose of this research study is to determine the preliminary safety of TP-1454 alone, or TP-1454 in combination with ipilimumab and nivolumab, at different doses to find out what effects, if any, it has on people with solid tumors. This study will also gain information about the pharmacokinetics or PK (the process by which a drug is absorbed, distributed, metabolized and eventually eliminated by the body) and pharmacodynamic (PD) biomarkers (which are used to examine the drug effect on the body and/or the tumor).
Protocol No
TOLERO-TP-1454-101
Sub Category
An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 Naïve and PD-(L)1 Pretreated Patient Populations with Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy
Three cohorts (groups) of subjects will be enrolled into the Module A part of the study based on cancer diagnosis, previous treatment and how the cancer responded to the previous treatment that was given. In Cohort 1 patients with gastroesophageal adenocarcinoma will be tested; Cohort 2 will test patients with any type of solid tumor cancer that benefitted previously from an anti-PD-1/PD-(L)1 treatment; and Cohort 3 will test patients that did not benefit from a previous anti-PD-1/PD-(L)1 treatment. The types of solid tumor cancers to be enrolled into Cohort 3 will include: previously treated colorectal cancer, merkel cell carcinoma, and squamous cell skin carcinoma; squamous cancers of the head and neck, cervix, anus,
penis, esophagus, and vulva; hepatocellular carcinoma; biliary tract carcinoma, small-cell lung cancer;
and mesothelioma.
penis, esophagus, and vulva; hepatocellular carcinoma; biliary tract carcinoma, small-cell lung cancer;
and mesothelioma.
Protocol No
BI-1381-0009-MULTI31
Sub Category
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies
Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
Protocol No
ADP-0000-001-SCR
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Protocol No
TORAY-950P1V02